1) PLGA microspheres
PLGA微球
1.
Preparation and property of bupivacaine hydrochloride PLGA microspheres for local anesthesia;
局部麻醉用缓释盐酸布比卡因PLGA微球的制备及特性研究
2.
Objective This paper focused on adjusting the release rates of risperidone from PLGA microspheres by co-encapsulating Mg(OH)2.
目的用氢氧化镁调节利培酮PLGA微球的释放速度。
3.
In this study,poly(lactic-co-glycolic acid )(PLGA) is used as a kind of relatively ideal carrier of drug controlled delivery to prepare the bFGF-PLGA microspheres which contain bFGF as the model drug,by the method of water in oil in water(w_1/o/w_2).
采用体外释放实验来验证PLGA微球作为bFGF控制释放载体的可行性。
2) PLGA microsphere
PLGA微球
1.
Preparation and release behavior of chitosan scaffolds encapsulating proteins loaded in PLGA microspheres;
包埋PLGA微球壳聚糖支架的构建及其对蛋白释放的调节
2.
Preparation and in vitro release behavior of the gentamicin sulfate-encapsulated PLGA microspheres;
硫酸庆大霉素/PLGA微球具有显著的药物缓释作用,体外释放30d的累积释药率达80%以上。
3) Liposome-encapsulated vaccine
PLGA微球疫苗
4) intereron α-2b PLGA microspheres
干扰素α-2b PLGA微球
1.
OBJECTIVE To develop an enzyme linked immunosorbent assay(ELISA) method for the content determination of intereron α-2b PLGA microspheres in the serum of rats and study the pharmacokinetics and bioavailability of in rats after subcutaneous administration.
结论ELISA法灵敏度高、重复性好,可作为干扰素α-2b PLGA微球临床前药动学的检测方法;干扰素α-2b PLGA微球具有明显的缓释作用,显著提高了干扰素α-2b的生物利用度。
5) PLGA microparticles
PLGA微囊
1.
The DCs were pulsed and chased with OVA encapsulated in PLGA microparticles and then fixed before the addition of OVA\|specific DO11·GFP T hybridom cells to analyse the degree of antigen presentation.
本研究在体外将含卵清蛋白 (OVA)的PLGA微囊与小鼠骨髓诱导的树突细胞 (BM DC)相互作用 ,然后用卵清蛋白特异性杂交瘤T细胞检测OVA抗原在BM DC表面的表达 ,结果显示 :PLGA微囊可以在体外显著促进BM DC对OVA抗原的呈递。
补充资料：可降解淀粉微球和生物降解白蛋白微球阻滞法
可降解淀粉微球和生物降解白蛋白微球阻滞法
介入放射学技术。介入性局部化疗之前，把二者注入靶动脉，可暂时减少动脉血流，再行化疗药物灌注，以减少血液冲刷，保持局部化疗药物浓度的技术。与其他中期和长期栓塞微球不同，DSM和BAM仅造成数十分钟的血流量减少，待其被降解后血流可恢复至以前水平。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条